Skip to content
VintaBio logo — VintaBio delivers customized process development and GMP man...

VintaBio

VintaBio delivers customized process development and GMP manufacturing service for cell and gene therapy.

Founded 2020 United States Philadelphia, United States 31 employees Venture round Total: $64.00M Biotechnology, Health and Wellness +1

General Information

Company Name VintaBio
Founded Year 2020
Location United States Philadelphia, United States
Employees 31
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with VintaBio. To contact VintaBio, visit vintabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does VintaBio compare?

A PDF of VintaBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting VintaBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About VintaBio

VintaBio delivers customized process development and GMP manufacturing services for cell and gene therapy. The company's development and manufacturing team has over a century of experience in the cell and gene therapy space and has been involved in the development of some of the most advanced therapies on the market. Situated in the historic Navy Yards of Philadelphia, an epicenter of cell and gene therapy innovation, VintaBio specializes in developing and manufacturing consistent, high-quality viral vectors, addressing an underserved area of CGT development. Co-founded by Junwei Sun and Dr. Shangzhen Zhou, who were pivotal in the development of the AAV vectors behind the first two FDA-approved gene therapies and the lentiviral vector for the first FDA-approved cell therapy, the company has raised a substantial $64 million in venture funding. This funding has facilitated the development of a new 22,500 square foot facility in Philadelphia, specifically designed for efficient cell and gene therapy manufacturing. The latest $64.00M Venture Round investment on 11th April 2023 was led by Decheng Capital.

Business keywords: cell therapy, gene therapy, process development, GMP manufacturing, viral vectors, AAV vectors, lentiviral vectors, venture funding, Philadelphia, innovation, FDA-approved therapies, facility development, team expertise, Navy Yards

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $64.00M 1
Decheng Capital
11 Apr 2023

VintaBio Alternatives & Competitors

View All Alternatives
VintaBio vs

End-to-end ATMP CDMO/CRO that provides innovative offerings at each stage for biopharmaceutical prod...

Series B
46 employees
Biotechnology, Health and Wellness
VintaBio vs

Our mission is to leverage the power of gene and cell therapy to reduce human suffering from serious...

Series F
26 employees
Biotechnology, Health Care
VintaBio vs

GMP Contract Manufacturing Organization for Biological Therapies and Vaccines for Human Clinical Tri...

28 employees
Biotechnology, Health Care

FAQ About VintaBio

VintaBio delivers customized process development and GMP manufacturing service for cell and gene therapy.
VintaBio was founded in 2020.
VintaBio is headquartered in Philadelphia, United States.
VintaBio operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on cell therapy, gene therapy, process development and GMP manufacturing.
VintaBio has approximately 31 employees.
VintaBio has completed 1 funding round, raising a total of $64.00M. The latest funding stage is Venture round.
Top alternatives and competitors to VintaBio include Porton Advanced | ATMP CDMO/CRO, American Gene Technologies® International Inc., Waisman Biomanufacturing, WuXi Advanced Therapies, StrideBio, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VintaBio and Porton Advanced | ATMP CDMO/CRO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VintaBio, https://bouncewatch.com/company/vintabio, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout